A Response to: Letter to the Editor Regarding "Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder"

Neurol Ther. 2022 Sep;11(3):1445-1449. doi: 10.1007/s40120-022-00378-0. Epub 2022 Jul 2.
No abstract available

Keywords: Aquaporin-4 immunoglobulin G-positive; Bayesian network meta-analysis; Eculizumab; Inebilizumab; Matching-adjusted indirect comparison; Neuromyelitis optica spectrum disorder; Randomized controlled trial; Satralizumab.

Publication types

  • Letter